Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: Correlation with clinicopathological criteria

Oncology Reports

Volumn 29, Issue 3, 2013, Pages 1043-1052

  Harlé, Alexandre ^a,b   Lion, Maëva ^a,b   Lozano, Nicolas ^a   Husson, Marie ^a   Harter, Valentin ^a   Genin, Pascal ^a,b   Merlin, Jean Louis ^a,b  

^a CENTRE ALEXIS VAUTRIN   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Breast cancer; PCR amplification refractory mutation system; PCR high resolution melting assay; PIK3CA mutations

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLUTAMIC ACID; HISTIDINE; LEUCINE; LYSINE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B;

ADULT; AGE; ALLELE; AMINO ACID SUBSTITUTION; AMPLIFICATION REFRACTORY MUTATION ANALYSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVE SITE; EXON; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NUCLEIC ACID ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; EXONS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; POINT MUTATION; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; TRANSITION TEMPERATURE;

EID: 84872801531     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2229     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Engelman JA, Luo J and Cantley LC: The evolution of phospha-tidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619, 2006. (Pubitemid 44100518)
3. Tokunaga E, Oki E, Egashira A, et al: Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 8: 27-36, 2008. (Pubitemid 351237907)
4. McAuliffe PF, Meric-Bernstam F, Mills GB and Gonzalez-Angulo AM: Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer 10: S59-S65, 2010.
5. Wang L, Zhang Q, Zhang J, et al: PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 11: 248, 2011.
6. Jiang BH and Liu LZ: PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 102: 19-65, 2009.
7. Bachman KE, Argani P, Samuels Y, et al: The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3: 772-775, 2004. (Pubitemid 41351083)
8. Karakas B, Bachman KE and Park BH: Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 94: 455-459, 2006. (Pubitemid 43289745)
9. Dunlap J, Le C, Shukla A, et al: Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 120: 409-418, 2009.
10. Orlando L, Schiavone P, Fedele P, et al: Molecularly targeted endocrine therapies for breast cancer. Cancer Treat Rev 36: S67-S71, 2010.
11. Miller TW, Balko JM and Arteaga CL: Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 29: 4452-4461, 2011.
12. Abramson V and Arteaga CL: New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Clin Cancer Res 17: 952-958, 2011.
13. Ma CX, Crowder RJ and Ellis MJ: Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors. Steroids 76: 750-752, 2011.
14. Razis E, Bobos M, Kotoula V, et al: Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastu-zumab therapy in metastatic breast cancer. Breast 128: 447-456, 2011.
15. Dave B, Migliaccio I, Gutierrez MC, et al: Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 29: 166-173, 2011.
16. Esteva FJ, Guo H, Zhang S, et al: PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177: 1647-1656, 2010.
17. Baselga J: Treatment of HER2-overexpressing breast cancer. Ann Oncol 21: vii36-40, 2011.
18. Garrett JT and Arteaga CL: Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther 11: 793-800, 2011.
19. Tanaka H, Yoshida M, Tanimura H, et al: The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res 17: 3272-3281, 2011.
20. Dan S, Okamura M, Mukai Y, et al: ZSTK474, a specific phos-phatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo. Eur J Cancer 48: 936-943, 2012.
21. Bibeau F, Frugier H, Denouel A, Sabourin JC and Boissiere-Michot F: Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view. Bull Cancer 96: S15-S22, 2009 (In French).
22. Vorkas PA, Poumpouridou N, Agelaki S, Kroupis C, Georgoulias V and Lianidou ES: PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method. J Mol Diagn 12: 697-704, 2010.
23. Board RE, Thelwell NJ, Ravetto PF, et al: Multiplexed assays for detection of mutations in PIK3CA. Clin Chem 54: 757-760, 2008. (Pubitemid 351573719)
24. Dumont AG, Dumont SN and Trent JC: The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer. Chin J Cancer 31: 327-334, 2012.
25. Barbareschi M, Buttitta F, Felicioni L, et al: Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 13: 6064-6069, 2007. (Pubitemid 350075063)
26. Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH and Tzen CY: PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol 15: 1064-1069, 2008.
27. Lerma E, Catasus L, Gallardo A, et al: Exon 20 PIK3CA mutations decrease survival in aggressive (HER-2 positive) breast carcinomas. Virchows Arch 453: 133-139, 2008.
28. Cizkova M, Susini A, Vacher S, et al: PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups. Breast Cancer Res 14: R28, 2012.
29. Aleskandarany MA, Rakha EA, Ahmed MA, et al: PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat 122: 45-53, 2009.
30. Campbell IG, Russell SE, Choong DY, et al: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64: 7678-7681, 2004. (Pubitemid 39446895)
31. Levine DA, Bogomolniy F, Yee CJ, et al: Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11: 2875-2878, 2005. (Pubitemid 40525186)
32. Miron A, Varadi M, Carrasco D, et al: PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 70: 5674-5678, 2010.
33. Wu G, Xing M, Mambo E, et al: Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 7: R609-R616, 2005.
34. Kalinsky K, Jacks LM, Heguy A, et al: PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15: 5049-5059, 2009.
35. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M and Noguchi S: Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 13: 408-414, 2007. (Pubitemid 46225343)
36. Ellis MJ, Lin L, Crowder R, et al: Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 119: 379-390, 2010.
37. Perez-Tenorio G, Alkhori L, Olsson B, et al: PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 13: 3577-3584, 2007. (Pubitemid 46955118)
38. Baker CL, Vaughn CP and Samowitz WS: A PIK3CA pyrose-quencing-based assay that excludes pseudogene interference. J Mol Diagn 14: 56-60, 2012.
39. Tougeron D, Lecomte T, Pages JC, et al: Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in meta-static colorectal cancer. J Clin Oncol 30: 3520, 2012.